These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11824989)

  • 1. A serosurvey evaluation of the school-based measles 'catch-up' immunisation campaign in Victorian school-aged children.
    Riddell MA; Leydon JA; Ugoni A; Kelly HA
    Aust N Z J Public Health; 2001 Dec; 25(6):529-33. PubMed ID: 11824989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual susceptibility to measles among young adults in Victoria, Australia following a national targeted measles-mumps-rubella vaccination campaign.
    Kelly HA; Gidding HF; Karapanagiotidis T; Leydon JA; Riddell MA
    BMC Public Health; 2007 Jun; 7():99. PubMed ID: 17555601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia.
    Kelly H; Riddell MA; Gidding HF; Nolan T; Gilbert GL
    Vaccine; 2002 Aug; 20(25-26):3130-6. PubMed ID: 12163264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological assessment of measles-rubella vaccination catch-up campaign among university students.
    Takeuchi J; Goto M; Kawamura T; Hiraide A
    Pediatr Int; 2014 Jun; 56(3):395-9. PubMed ID: 24417932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasons for non-uptake of measles, mumps, and rubella catch up immunisation in a measles epidemic and side effects of the vaccine.
    Roberts RJ; Sandifer QD; Evans MR; Nolan-Farrell MZ; Davis PM
    BMJ; 1995 Jun; 310(6995):1629-32. PubMed ID: 7795447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.
    Amela C; Pachón I; de Ory F
    Eur J Epidemiol; 2003; 18(1):71-9. PubMed ID: 12705626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus.
    Molyneaux PJ; Mok JY; Burns SM; Yap PL
    J Infect; 1993 Nov; 27(3):251-3. PubMed ID: 8308316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study.
    Mossong J; Putz L; Schneider F
    Epidemiol Infect; 2004 Jan; 132(1):11-8. PubMed ID: 14979584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sero-epidemiology of measles and mumps in Korea: impact of the catch-up campaign on measles immunity.
    Kim SS; Han HW; Go U; Chung HW
    Vaccine; 2004 Dec; 23(3):290-7. PubMed ID: 15530670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of mumps and immunity to measles, mumps and rubella among US military recruits, 2000-2004.
    Eick AA; Hu Z; Wang Z; Nevin RL
    Vaccine; 2008 Jan; 26(4):494-501. PubMed ID: 18155326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 18. Seroprevalence of measles- and mumps-specific immunoglobulin G among Japanese healthcare students increased during 2007-2012.
    Kimura T; Tsunekawa K; Ogiwara T; Tokue Y; Nara M; Inoue T; Obuchi T; Suto C; Ohshima K; Murakami M
    Jpn J Infect Dis; 2013; 66(5):411-5. PubMed ID: 24047740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A; Boxall N; Amirthalingam G; Maddock L; Balasegaram S; Mindlin M
    Vaccine; 2014 Feb; 32(10):1147-52. PubMed ID: 24440207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.